Hillstream BioPharma Signs Option Agreement to Advance Next Generation Anti-MUC1-C Agents
Hillstream BioPharma announced signing an exclusive option agreement with Dana-Farber Cancer Institute to licence technology targeting the MUC1-C oncoprotein. This agreement allows Hillstream to leverage Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumours, which represents a major unmet need for patients. Under an exclusive option agreement which, if converted into an exclusive licence agreement, will allow Hillstream to develop anti-MUC1-C antibodies to supply Hillstream's Quatramer-based lead candidate. HSB-1216 targets CSC by inducing ferroptosis. This approach, combineing HSB-1216 for conjugation with MUC1-C antibodies, is highly synergistic in eliminating CSCs, effective for long-term responses and treatments. MUC1-C is effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC). MUC1-C is considered necessary for multiple hallmarks of the cancer cell, including (i) the persister cell (PC) state, (ii) drug resistance, (iii) immunosuppression, and (iv) poor clinical outcomes

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!